Third quarter: Orthopaedics strong but CRM & DESs (drug-eluting stents) still suffering
This article was originally published in Clinica
Abbott Laboratories' reported medical products sales rose by 20% in the third quarter, boosted by the acquisition of Guidant's vascular products, which helped Abbott Vascular achieve sales of $351m. Diagnostics revenues were up 8.6% at $1bn, with the US business providing 9.9% growth to $337m, driven by the launch of the Prism blood screening system and double-digit growth in molecular and point of care testing. Diabetes care revenues increased by 4.9% to $283m, with growth coming from the non-US markets and US sales virtually flat at $133m.
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?
Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.